Shelley Shapiro

9PUBLICATIONS
19CO-AUTHORS
Respiratory diseasesCell physiologyGene and molecular therapyToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 11, 2024
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

Oksana A Shlobin, Eric Shen, Stephen J Wort

|Aug 26, 2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.

Sylvia M Nikkho, Manuel J Richter, Eric Shen

|Feb 14, 2022
Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations.

Gautam Ramani, Steven Cassady, Eric Shen

|Nov 12, 2021
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.

Steven D Nathan, Victor F Tapson, Jean Elwing

|Nov 04, 2021
Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily.

Shelley Shapiro, Stacy Mandras, Ricardo Restrepo-Jaramillo

|Apr 10, 2021
Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.

Stacy Mandras, Gabor Kovacs, Horst Olschewski

Pageof 2

Frequent Collaborators

5 joint publications

Steven D Nathan

2 joint publications

Aaron Waxman

2 joint publications

Sylvia M Nikkho

1 joint publications

Stacy Mandras